Viatris Wins Patent Battle Against Novo Nordisk Over Generic Wegovy

A federal district court in Delaware has ruled in favor of Viatris查看公司主页 in a patent dispute with Novo Nordisk查看公司主页 over the generic manufacturer's proposed copy of the blockbuster obesity (搜索)搜索该疾病 drug Wegovy查看药品详情 (semaglutide查看药品详情). The decision removes a significant patent barrier for Viatris' generic version, which is currently awaiting FDA approval.

Court Rules Against Patent Infringement Claims

Chief Judge Colm F. Connolly granted Viatris查看公司主页' request for judgment, finding that the company's generic semaglutide查看药品详情 product does not infringe US Patent No. 9,764,003. The patent covers the use of the glucagon-like peptide-1 receptor agonist (GLP-1RA) without other therapeutic agents for weight loss or to treat diabetes (搜索)搜索该疾病 or hypertension (搜索)搜索该疾病.

Novo Nordisk查看公司主页 had alleged that five patents cover Wegovy查看药品详情 and that Viatris查看公司主页' Mylan Pharmaceuticals unit's generic version would infringe these patents. However, the court focused on a critical distinction in how the products would be labeled and prescribed.

Key Legal Arguments and Decision

Viatris查看公司主页 successfully argued that its product label does not instruct patients or physicians to administer the drug without another therapeutic agent for weight loss or to treat diabetes (搜索)搜索该疾病 or hypertension (搜索)搜索该疾病—a key element of Novo Nordisk查看公司主页's patented method.

The court documents reveal that while Viatris查看公司主页' label instructs physicians and patients not to co-administer the product with other semaglutide查看药品详情-containing products or GLP-1RAs, it does not prohibit co-administration with other therapeutic agents. The judge concluded that Viatris' label "did not intend to preclude the coadministration of those other agents with its semaglutide product."

The ruling stated that because the proposed label "does not encourage, promote, or recommend" the use of the product without other therapies, Viatris查看公司主页' drug does not induce infringement of the "administered without another therapeutic agent" limitation of the patent's first claim.

Market Impact and Financial Implications

The decision has significant financial implications given the substantial market for obesity (搜索)搜索该疾病 treatments. GlobalData analysis shows global sales of Wegovy查看药品详情 reached $8.4 billion in 2024, with forecasts projecting sales of $21.39 billion by 2030.

The broader obesity (搜索)搜索该疾病 market across seven major markets (France, Germany, Italy, Japan, Spain, the UK, and the US) is predicted to exceed $173.5 billion by 2031, according to GlobalData.

Industry Response and Ongoing Litigation

A Viatris查看公司主页 spokesperson expressed satisfaction with the outcome, stating: "We are pleased with the District Court's favourable decision finding non-infringement of the '003 patent related to Wegovy查看药品详情, which removes it from the patent trial scheduled to begin in March 2026. We have no further comment on this ongoing legal matter at this time."

Novo Nordisk查看公司主页 declined to provide further comment while the case remains ongoing.

Broader Patent Landscape

This ruling represents the latest development in ongoing patent disputes surrounding semaglutide查看药品详情 products. Ten months prior, Novo Nordisk查看公司主页 and Viatris查看公司主页 settled a separate patent dispute over Novo Nordisk's Ozempic查看药品详情 (semaglutide), though the settlement terms were not disclosed.

Novo Nordisk查看公司主页 has filed multiple lawsuits against various entities, including medical spas, wellness clinics, and pharmacies for selling semaglutide查看药品详情-containing products. In April 2025, a US judge rejected efforts by the Outsourcing Facilities Association, representing compounding companies, to continue manufacturing alternative versions of semaglutide after the FDA-declared shortage was resolved in mid-February.

The Delaware court's decision eliminates one patent obstacle for Viatris查看公司主页' generic Wegovy查看药品详情, though other patent challenges may remain as the company seeks to bring its version to market.